10:44 AM EDT, 07/29/2026 (MT Newswires) -- The US Food and Drug Administration closed its inspection of Alvotech's (Z450.F, Z45.F) manufacturing facility in Reykjavik, Iceland, with a classification of voluntary action indicated. Chief Executive Officer Lisa Graver said Wednesday that the biosimilar specialist is confident that the actions it has taken have "effectively" addressed the US FDA's identified observations. The inspection was conducted in May.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.